Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 1, 2010, Pages 291-297

  Hohoff, Christa ^a   Ponath, Gerald ^a   Freitag, Christine M ^b,c   Kästner, Florian ^a   Krakowitzky, Petra ^a   Domschke, Katharina ^a   Koelkebeck, Katja ^a   Kipp, Frank ^a   Von Eiff, Christof ^a,d   Deckert, Jürgen ^a,e   Rothermundt, Matthias ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d Wyeth Pharma GmbH   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Association; Functional polymorphisms; mRNA expression; Postmortem frontal cortex; S100 calcium binding protein b

Indexed keywords

GENE PRODUCT; MESSENGER RNA; PROTEIN S100B; SEROTONIN; SEROTONIN 1A; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DEMENTIA; FRONTAL CORTEX; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; NERVE GROWTH FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1A; RISK FACTORS; RNA, MESSENGER; S100 PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 73949134288     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30950     Document Type: Article

References (39)

1. Allore R, O'Hanlon D, Price R, Neilson K, Willard HF, Cox DR, Marks A, Dunn RJ. 1988. Gene encoding the beta subunit of S100 protein is on chromosome 21: Implications for Down syndrome. Science 239:1311-1313.
2. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265.
3. Baune BT, Hohoff C, Mortensen LS, Deckert J, Arolt V, Domschke K. 2007. Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: A female specific effect? Depress Anxiety 25:920-925.
4. Cassidy F, Zhao C, Badger J, Claffey E, Dobrin S, Roche S, McKeon P. 2007. Genome-wide scan of bipolar disorder and investigation of population stratification effects on linkage: Support for susceptibility loci at 4q21, 7q36, 9p21, 12q24, 14q24, and 16p13. Am J Med Genet Part B 144B:791-801.
5. Demirhan O, Taştemir D. 2003. Chromosome aberrations in a schizophrenia population. Schizophr Res 65:1-7.
6. Donato R. 2001. S100:Amultigenic family of calcium-modulate proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33:637-668.
7. Donato R. 2007. RAGE: A single receptor for several ligands and different cellular responses. The case of certain S100 proteins. Curr Mol Med 7:711-724.
8. Eriksen JL, Gillespie R, Druse MJ. 2002. Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Res Dev Brain Res 139:97-105.
9. Fu L, Ma W, Benchimol S. 1999. A translation repressor element resides in the 3' untranslated region of human p53 mRNA. Oncogene 18:6419-6424.
10. Heizmann CW, Fritz G, Schaefer BW. 2002. S100 proteins: Structure, functions and pathology. Front Biosci 7:d1356-d1368.
11. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W,Ramic D, Williams J, Goate A, Hardy J,Owen MJ. 1999.A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 8:237-245.
12. Lambert JC, Ferreira S, Gussekloo J, Christiansen L, Brysbaert G, Slagboom E, Cottel D, Petit T, Hauw JJ, DeKosky ST, Richard F, Berr C, Lendon C, Kamboh MI, Mann D, Christensen K, Westendorp R, Amouyel P. 2007. Evidence for the association of the S100beta gene with low cognitive performance and dementia in the elderly. Mol Psychiatry 12:870-880.
13. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531.
14. Ling SH, Tang YL, Jiang F, Wiste A, Guo SS, Weng YZ, Yang TS. 2007. Plasma S-100B protein in Chinese patients with schizophrenia: Comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 41:36-42.
15. Lins H, Wallesch CW, Wunderlich MT. 2005. Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections. Acta Neurol Scand 112:303-308.
16. Liu J, Shi Y, Tang J, Guo T, Li X, Yang Y, Zhao X, He G, Feng G, Gu N, Zhu S, Liu H, He L. 2005. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 328:335-341.
17. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, Marlowe L, Kaleem M, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson JV, Holmans P, Heward CB, Reiman EM, Stephan D, Hardy J. 2007. A survey of genetic human cortical gene expression. Nat Genet 39:1494-1499.
18. Nichols DE, Nichols CD. 2008. Serotonin receptors. Chem Rev 108:1614-1641.
19. Nylén K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, Nellgård B, Rosengren L. 2008. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) 150:221-227.
20. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. 2001. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 39:409-413.
21. Roche S, Cassidy F, Zhao C, Badger J, Claffey E, Mooney L, Delaney C, Dobrin S, McKeonP. 2007. Candidate gene analysis of 21q22: Support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet Part B 144B:1094-1096.
22. Rothe C, Gutknecht L, Freitag C, Tauber R,Mössner R, Franke P, Fritze J, Wagner G, Peikert G, Wenda B, Sand P, Jacob C, Rietschel M, Nöthen MM, Garritsen H, Fimmers R, Deckert J, Lesch KP. 2004. Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol 7:189-192.
23. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H. 2001. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6:445-449.
24. Rothermundt M, Peters M, Prehn JH, Arolt V. 2003. S100B in brain damage and neurodegeneration. Microsc Res Tech 60:614-632.
25. Rothermundt M, Falkai P, Ponath G, Abel S, Bürkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V. 2004a. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9:897-899.
26. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. 2004b. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29:1004-1011.
27. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, Suslow T, Peters M, Kaestner F, Heindel W, Arolt V, Pfleiderer B. 2007. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myoinositol. Prog Neuropsychopharmacol Biol Psychiatry 31:361-436.
28. Schenatto CB, Xavier RM, Bredemeier M, Portela LV, Tort AB, Dedavid e Silva TL, Souza DO,Brenol JC. 2006. Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis 65:829-831.
29. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE. 2002. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 13:1675-1678.
30. Schroeter ML, Abdul-Khaliq H, Frühauf S, Höhne R, Schick G, Diefenbacher A, Blasig IE. 2003. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 62:231-236.
31. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. 2008. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 111:271-280.
32. Sen J, Belli A. 2007. S100B in neuropathologic states: TheCRPof the brain? J Neurosci Res 85:1373-1380.
33. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT. 2006. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 77:1284-1287.
34. Stephens M, Donnelly P. 2003. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169.
35. Terry AV Jr, Buccafusco JJ, Wilson C. 2008. Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 195:30-38.
36. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. 2006. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:515-524.
37. Vasudevan S, Tong Y, Steitz JA. 2007. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 318:1931-1934.
38. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. 2006. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 11:224-226.
39. Wilusz CJ, WormingtonM,PeltzSW.2001. The cap-to-tail guide tomRNA turnover. Nat Rev Mol Cell Biol 2:237-246.